Category: News

Accelagen Staff Announcement: Janelle Hanley

April 28, 2022
It is our pleasure to formally welcome another member to Accelagen’s Australian team this week. Janelle Hanley is our new Senior Quality Assurance Associate, a vital role within our growing business. Janelle is an experienced director of Quality Assurance with a demonstrated history of working in the hospital and health care industries. She is highly

Accelagen Staff Announcement: Kylie Lord

April 11, 2022
Accelagen is thrilled to officially welcome Kylie Lord as our company’s first CFO. Our business continues to grow rapidly in Australia, and we are building our team to support that growth. Kylie started with Accelagen in 2021 as a member of our advisory board, and the synergies were there from the get-go. Not only was

Accelagen Biometrics Team announcement

March 31, 2022
Accelagen is thrilled to announce that we have established a dedicated Biometrics team, welcoming Elisa Young as Head of Biostatistics, and Hana Kazda as Head of Data Management, with more new hires to follow soon. Accelagen’s global reputation, coupled with explosive demand for local CROs to service Australia’s growing clinical trial market, has led to

Accelagen Staff Announcement: Melanie Scheepers

March 20, 2022
Accelagen is thrilled to welcome Melanie Scheepers to the Accelagen team as the company’s first dedicated Pharmacovigilance Associate. Our business continues to grow rapidly in Australia, and we are building our team to support that growth. Melanie is a highly experienced PV and Safety leader with over 2o years’ international and local experience. After completing

Accelagen Staff Announcement: Melissa Giuliani

December 22, 2021
Accelagen is pleased to announce the appointment of Melissa Giuliani as Head of Business Development & Marketing. Melissa brings a strong background in global brand, marketing, and business growth to the growing bio-pharmaceutical & medical device development organisation, from her more than 20-year career across pharmaceuticals, and FMCG markets. Accelagen’s CEO, Greg Plunkett’s vision to

Orphan Drug Designation: a pathway to accessible treatment for rare diseases

August 18, 2021
The term ‘Orphan Drugs’ refers to medicines developed to treat medical conditions, considered to be rare. In Australia, if a medicine is intended to treat a condition which affects fewer than 5 in 10,000 individuals, it may fit within the definitions of an Orphan Drug. With a low number of patients who may be eligible

Accelagen facilitates LEDAGA Approval in Australia

August 3, 2021
LEDAGA® (Chlormethine hydrochloride) – TGA APPROVAL Accelagen, a Melbourne based Regulatory Affairs, Clinical Research and Development Organisation, are pleased to be an integral part of the approval of LEDAGA® by the Therapeutic Goods Administration (TGA) on behalf of the Australian office of Recordati Rare Diseases. LEDAGA, indicated for the topical treatment of mycosis fungoides-type cutaneous

Accelagen driving development of new candidate for COVID-19 Vaccine

September 1, 2020
1st September 2020 Accelagen is excited to announce the initiation of a new COVID-19 vaccine trial, commencing in Melbourne on Tuesday 1st September! One of the largest vaccine manufacturer’s in the world has entrusted Accelagen to initiate this important first study to support the next stage of development of this novel vaccine. Following the successful

Plunkett Consulting Group to attend BioKorea 2018

April 27, 2018
Plunkett Consulting Group will be attending the BioKorea International Convention  in Seoul during 9 – 11 May 2018.  This is an exciting opportunity to meet with research leaders in Asia and showcase our Company’s capabilities internationally. Really looking forward to a great outcome!

Introducing eCTD Publishing Service

April 27, 2018
Regulatory publishing demands are growing, and soon all submissions must be submitted in electronic CTD (eCTD) format.  In recognising this, Plunkett Consulting Group are excited by the opportunity to add regulatory publishing to our suite of services.  We have access to the Extedo eCTDmanager software that allows us to publish electronic regulatory documentation for not